Remibrutinib: FDA decision for chronic spontaneous urticaria in H2 205 (Novartis) - Apr 29, 2025 - Q1 2025 Results: Regulatory submission for Hidradenitis suppurativa in 2028 or later
FDA approval • Filing • Chronic Spontaneous Urticaria • Hidradenitis Suppurativa • Immunology
|